Cargando…

The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure

AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinsino, Alberto, Fabbri, Matteo, Braghieri, Lorenzo, Bohn, Bruno, Gaudig, Antonia J., Kim, Andrea, Takeda, Koji, Naka, Yoshifumi, Sayer, Gabriel T., Uriel, Nir, Demmer, Ryan T., Faillace, Robert T., Husain, Syed A., Mohan, Sumit, Colombo, Paolo C., Yuzefpolskaya, Melana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715858/
https://www.ncbi.nlm.nih.gov/pubmed/35762103
http://dx.doi.org/10.1002/ehf2.13975
_version_ 1784842551067410432
author Pinsino, Alberto
Fabbri, Matteo
Braghieri, Lorenzo
Bohn, Bruno
Gaudig, Antonia J.
Kim, Andrea
Takeda, Koji
Naka, Yoshifumi
Sayer, Gabriel T.
Uriel, Nir
Demmer, Ryan T.
Faillace, Robert T.
Husain, Syed A.
Mohan, Sumit
Colombo, Paolo C.
Yuzefpolskaya, Melana
author_facet Pinsino, Alberto
Fabbri, Matteo
Braghieri, Lorenzo
Bohn, Bruno
Gaudig, Antonia J.
Kim, Andrea
Takeda, Koji
Naka, Yoshifumi
Sayer, Gabriel T.
Uriel, Nir
Demmer, Ryan T.
Faillace, Robert T.
Husain, Syed A.
Mohan, Sumit
Colombo, Paolo C.
Yuzefpolskaya, Melana
author_sort Pinsino, Alberto
collection PubMed
description AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference between eGFR(CysC) and eGFR(sCr) may reflect muscle mass loss. We investigated the difference between eGFR(CysC) and eGFR(sCr) and its association with clinical outcomes in acute HF patients. METHODS AND RESULTS: A post hoc analysis was performed in 841 patients enrolled in three trials: Diuretic Optimization Strategy Evaluation (DOSE), Renal Optimization Strategies Evaluation (ROSE), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS‐HF). Intra‐individual differences between eGFRs (eGFR(diff)) were calculated as eGFR(CysC)–eGFR(sCr) at serial time points during HF admission. We investigated associations of (i) change in eGFR(diff) between baseline and day 3 or 4 with readmission‐free survival up to day 60; (ii) index hospitalization length of stay (LOS) and readmission with eGFR(diff) at day 60. eGFR(CysC) reclassified 40% of samples to more advanced kidney dysfunction. Median eGFR(diff) was −4 [−11 to 1.5] mL/min/1.73 m(2) at baseline, became more negative during admission and remained significantly different at day 60. The change in eGFR(diff) between baseline and day 3 or 4 was associated with readmission‐free survival (adjusted hazard ratio per standard deviation decrease in eGFR(diff): 1.14, P = 0.035). Longer index hospitalization LOS and readmission were associated with more negative eGFR(diff) at day 60 (both P ≤ 0.026 in adjusted models). CONCLUSIONS: In acute HF, a marked difference between eGFR(CysC) and eGFR(sCr) is present at baseline, becomes more pronounced during hospitalization, and is sustained at 60 day follow‐up. The change in eGFR(diff) during HF admission and eGFR(diff) at day 60 are associated with clinical outcomes.
format Online
Article
Text
id pubmed-9715858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97158582022-12-05 The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure Pinsino, Alberto Fabbri, Matteo Braghieri, Lorenzo Bohn, Bruno Gaudig, Antonia J. Kim, Andrea Takeda, Koji Naka, Yoshifumi Sayer, Gabriel T. Uriel, Nir Demmer, Ryan T. Faillace, Robert T. Husain, Syed A. Mohan, Sumit Colombo, Paolo C. Yuzefpolskaya, Melana ESC Heart Fail Original Articles AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference between eGFR(CysC) and eGFR(sCr) may reflect muscle mass loss. We investigated the difference between eGFR(CysC) and eGFR(sCr) and its association with clinical outcomes in acute HF patients. METHODS AND RESULTS: A post hoc analysis was performed in 841 patients enrolled in three trials: Diuretic Optimization Strategy Evaluation (DOSE), Renal Optimization Strategies Evaluation (ROSE), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS‐HF). Intra‐individual differences between eGFRs (eGFR(diff)) were calculated as eGFR(CysC)–eGFR(sCr) at serial time points during HF admission. We investigated associations of (i) change in eGFR(diff) between baseline and day 3 or 4 with readmission‐free survival up to day 60; (ii) index hospitalization length of stay (LOS) and readmission with eGFR(diff) at day 60. eGFR(CysC) reclassified 40% of samples to more advanced kidney dysfunction. Median eGFR(diff) was −4 [−11 to 1.5] mL/min/1.73 m(2) at baseline, became more negative during admission and remained significantly different at day 60. The change in eGFR(diff) between baseline and day 3 or 4 was associated with readmission‐free survival (adjusted hazard ratio per standard deviation decrease in eGFR(diff): 1.14, P = 0.035). Longer index hospitalization LOS and readmission were associated with more negative eGFR(diff) at day 60 (both P ≤ 0.026 in adjusted models). CONCLUSIONS: In acute HF, a marked difference between eGFR(CysC) and eGFR(sCr) is present at baseline, becomes more pronounced during hospitalization, and is sustained at 60 day follow‐up. The change in eGFR(diff) during HF admission and eGFR(diff) at day 60 are associated with clinical outcomes. John Wiley and Sons Inc. 2022-06-27 /pmc/articles/PMC9715858/ /pubmed/35762103 http://dx.doi.org/10.1002/ehf2.13975 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Pinsino, Alberto
Fabbri, Matteo
Braghieri, Lorenzo
Bohn, Bruno
Gaudig, Antonia J.
Kim, Andrea
Takeda, Koji
Naka, Yoshifumi
Sayer, Gabriel T.
Uriel, Nir
Demmer, Ryan T.
Faillace, Robert T.
Husain, Syed A.
Mohan, Sumit
Colombo, Paolo C.
Yuzefpolskaya, Melana
The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title_full The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title_fullStr The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title_full_unstemmed The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title_short The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
title_sort difference between cystatin c‐ and creatinine‐based assessment of kidney function in acute heart failure
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715858/
https://www.ncbi.nlm.nih.gov/pubmed/35762103
http://dx.doi.org/10.1002/ehf2.13975
work_keys_str_mv AT pinsinoalberto thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT fabbrimatteo thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT braghierilorenzo thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT bohnbruno thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT gaudigantoniaj thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT kimandrea thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT takedakoji thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT nakayoshifumi thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT sayergabrielt thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT urielnir thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT demmerryant thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT faillacerobertt thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT husainsyeda thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT mohansumit thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT colombopaoloc thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT yuzefpolskayamelana thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT pinsinoalberto differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT fabbrimatteo differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT braghierilorenzo differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT bohnbruno differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT gaudigantoniaj differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT kimandrea differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT takedakoji differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT nakayoshifumi differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT sayergabrielt differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT urielnir differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT demmerryant differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT faillacerobertt differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT husainsyeda differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT mohansumit differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT colombopaoloc differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure
AT yuzefpolskayamelana differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure